Abstract
JAK2V617F allele burden was prospectively measured in polycythemia vera (PV, n=52) and essential thrombocythemia (ET, n=39) patients receiving hydroxycarbamide (HC) and analyzed according to JAK2 46/1 haplotype and genotype of SLC14A1, SLC14A2 and ARG2 urea transporters. Molecular response (MR) was obtained in 68.7% and 38.9% of PV patients with GG and AA or GA genotype in SLC14A2, respectively (p=0.07). No significant differences were observed neither in PV nor in ET according to JAK2 46/1 haplotype, SLC14A1 and ARG2. In conclusion, JAK2 46/1 haplotype does not influence MR in HC treated patients and urea transporters polymorphisms display a minimal effect.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / therapeutic use
-
Arginase / genetics
-
Female
-
Gene Frequency
-
Genetic Predisposition to Disease*
-
Genotype
-
Haplotypes
-
Humans
-
Hydroxyurea / therapeutic use*
-
Janus Kinase 2 / genetics*
-
Male
-
Membrane Transport Proteins
-
Middle Aged
-
Mutation*
-
Myeloproliferative Disorders / drug therapy*
-
Myeloproliferative Disorders / genetics*
-
Outcome Assessment, Health Care
-
Polycythemia Vera / drug therapy
-
Polycythemia Vera / genetics
-
Prospective Studies
-
Thrombocythemia, Essential / drug therapy
-
Thrombocythemia, Essential / genetics
-
Urea Transporters
Substances
-
Antineoplastic Agents
-
Membrane Transport Proteins
-
Janus Kinase 2
-
Arginase
-
Hydroxyurea